Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.66 |
| ▸ | PRKX | P51817 | 1/20 | 0.66 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.66 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.66 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.55 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.55 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.55 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.55 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.55 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.55 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.55 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8934682 | 1.00 | MAP2K1 (1.00) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL12851130 | 0.88 | MAP2K1 (0.78) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL8938523 | 0.87 | MAP2K1 (0.76) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL8934414 | 0.85 | MAP2K1 (0.74) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL4005826 | 0.80 | ROCK1 (1.00) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL951238 | 0.80 | ROCK1 (1.00) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL4009239 | 0.80 | ROCK1 (1.00) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| Hydrochloric Acid SCHEMBL952513 | 0.79 | ROCK1 (0.98) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL13423105 | 0.78 | MAP2K1 (0.64) | MAP2K1ROCK1ROCK2PRKCDPRKX | |
| SCHEMBL8935750 | 0.78 | MAP2K1 (0.64) | MAP2K1ROCK1ROCK2PRKCDPRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910333-B1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2013-05-22 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | MAP2K1 1916/4885ROCK1 8/4885ROCK2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.